TY - JOUR
T1 - Presentation and outcomes of adrenal ganglioneuromas
T2 - A cohort study and a systematic review of literature
AU - Dages, Kelley N.
AU - Kohlenberg, Jacob D.
AU - Young, William F.
AU - Murad, Mohammad Hassan
AU - Prokop, Larry
AU - Rivera, Michael
AU - Dy, Benzon
AU - Foster, Trenton
AU - Lyden, Melanie
AU - McKenzie, Travis
AU - Thompson, Geoffrey
AU - Bancos, Irina
N1 - Funding Information:
This research was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health USA under award K23 DK121888. The views expressed are those of the author(s) and not necessarily those of the National Institutes of Health USA.
Publisher Copyright:
© 2021 John Wiley & Sons Ltd
PY - 2021/7
Y1 - 2021/7
N2 - Objective: To describe the presentation and outcomes of patients with adrenal ganglioneuromas (AGNs). Design: Single-centre retrospective cohort study (1 January 1995 to 31 December 2019) and systematic review of literature (1 January 1980 to 19 November 2019). Patients: Diagnosed with histologically confirmed AGN. Measurements: Baseline clinical, imaging and biochemical characteristics, recurrence rates and mortality. Subgroup analysis was performed on tumours with histologic elements of ganglioneuroma and pheochromocytoma (ie composite tumours). Results: The cohort study included 45 patients with AGN, 20 (44%) of which had composite tumours. Compared to pure AGN, patients with composite tumour were older (median age, 62.5 vs. 35 years, p <.001), had smaller tumours (median size, 3.9 vs. 5.7 cm, p =.016) and were discovered incidentally less frequently (65% vs. 84%, p =.009). No recurrences or ganglioneuroma-specific mortality occurred during follow-up (range, 0–266 months). The systematic review included 14 additional studies and 421 patients. The mean age of diagnosis was 39 years, and 47% were women. AGNs were discovered incidentally in 72% of patients, were predominantly unilateral (99%) and had a mean diameter of 5.8 cm and an unenhanced computed tomography (CT) attenuation of −118 to 49 Hounsfield units (HU). On imaging, 69% of AGNs were homogenous, 41% demonstrated calcifications, and 40% were lobulated. Conclusions: AGNs are rare benign tumours that present with variable imaging features including large size, unenhanced CT attenuation >20 HU, calcifications and lobulated shape. Imaging characteristics can assist in establishing a diagnosis and avoiding an unnecessary adrenalectomy. The association of pheochromocytomas with AGNs is frequent. Diagnosis should include biochemical testing.
AB - Objective: To describe the presentation and outcomes of patients with adrenal ganglioneuromas (AGNs). Design: Single-centre retrospective cohort study (1 January 1995 to 31 December 2019) and systematic review of literature (1 January 1980 to 19 November 2019). Patients: Diagnosed with histologically confirmed AGN. Measurements: Baseline clinical, imaging and biochemical characteristics, recurrence rates and mortality. Subgroup analysis was performed on tumours with histologic elements of ganglioneuroma and pheochromocytoma (ie composite tumours). Results: The cohort study included 45 patients with AGN, 20 (44%) of which had composite tumours. Compared to pure AGN, patients with composite tumour were older (median age, 62.5 vs. 35 years, p <.001), had smaller tumours (median size, 3.9 vs. 5.7 cm, p =.016) and were discovered incidentally less frequently (65% vs. 84%, p =.009). No recurrences or ganglioneuroma-specific mortality occurred during follow-up (range, 0–266 months). The systematic review included 14 additional studies and 421 patients. The mean age of diagnosis was 39 years, and 47% were women. AGNs were discovered incidentally in 72% of patients, were predominantly unilateral (99%) and had a mean diameter of 5.8 cm and an unenhanced computed tomography (CT) attenuation of −118 to 49 Hounsfield units (HU). On imaging, 69% of AGNs were homogenous, 41% demonstrated calcifications, and 40% were lobulated. Conclusions: AGNs are rare benign tumours that present with variable imaging features including large size, unenhanced CT attenuation >20 HU, calcifications and lobulated shape. Imaging characteristics can assist in establishing a diagnosis and avoiding an unnecessary adrenalectomy. The association of pheochromocytomas with AGNs is frequent. Diagnosis should include biochemical testing.
KW - adrenal imaging
KW - adrenal mass
KW - adrenalectomy
KW - composite tumour
KW - pheochromocytoma
UR - http://www.scopus.com/inward/record.url?scp=85102846729&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102846729&partnerID=8YFLogxK
U2 - 10.1111/cen.14460
DO - 10.1111/cen.14460
M3 - Article
C2 - 33721367
AN - SCOPUS:85102846729
SN - 0300-0664
VL - 95
SP - 47
EP - 57
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 1
ER -